Claims
- 1. A targeting construct comprising:
(a) a first polynucleotide sequence homologous to a platelet-activating factor receptor gene; (b) a second polynucleotide sequence homologous to the platelet-activating factor receptor gene; and (c) a selectable marker.
- 2. The targeting construct of claim 1, wherein the targeting construct further comprises a screening marker.
- 3. A method of producing a targeting construct, the method comprising:
(a) providing a first polynucleotide sequence homologous to a platelet-activating factor receptor gene; (b) providing a second polynucleotide sequence homologous to the platelet-activating factor receptor; (c) providing a selectable marker; and (d) inserting the first sequence, second sequence, and selectable marker into a vector, to produce the targeting construct.
- 4. A method of producing a targeting construct, the method comprising:
(a) providing a polynucleotide comprising a first sequence homologous to a first region of a platelet-activating factor receptor gene and a second sequence homologous to a platelet-activating factor receptor gene; (b) inserting a positive selection marker in between the first and second sequences to form the targeting construct.
- 5. A cell comprising a disruption in a platelet-activating factor receptor gene.
- 6. The cell of claim 5, wherein the cell is a murine cell.
- 7. The cell of claim 6, wherein the murine cell is an embryonic stem cell.
- 8. A non-human transgenic animal comprising a disruption in a platelet-activating factor receptor gene.
- 9. A cell derived from the non-human transgenic animal of claim 8.
- 10. A method of producing a transgenic mouse comprising a disruption in a platelet-activating factor receptor gene, the method comprising:
(a) introducing the targeting construct of claim 1 into a cell; (b) introducing the cell into a blastocyst; (c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and (d) breeding the chimeric mouse to produce the transgenic mouse.
- 11. A method of identifying an agent that modulates the expression of a platelet-activating factor receptor, the method comprising:
(a) providing a non-human transgenic animal comprising a disruption in a platelet-activating factor receptor gene; (b) administering an agent to the non-human transgenic animal; and (c) determining whether the expression of platelet-activating factor receptor in the non-human transgenic animal is modulated.
- 12. A method of identifying an agent that modulates the function of a platelet-activating factor receptor, the method comprising:
(a) providing a non-human transgenic animal comprising a disruption in a platelet-activating factor receptor gene; (b) administering an agent to the non-human transgenic animal; and (c) determining whether the function of the disrupted platelet-activating factor receptor gene in the non-human transgenic animal is modulated.
- 13. A method of identifying an agent that modulates the expression of platelet-activating factor receptor, the method comprising:
(a) providing a cell comprising a disruption in a platelet-activating factor receptor gene; (b) contacting the cell with an agent; and (c) determining whether expression of the platelet-activating factor receptor is modulated.
- 14. A method of identifying an agent that modulates the function of a platelet-activating factor receptor gene, the method comprising:
(a) providing a cell comprising a disruption in a platelet-activating factor receptor gene; (b) contacting the cell with an agent; and (c) determining whether the function of the platelet-activating factor receptor gene is modulated.
- 15. The method of claim 13 or claim 14, wherein the cell is derived from the non-human transgenic animal of claim 8.
- 16. An agent identified by the method of claim 11, claim 12, claim 13, or claim 14.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Application No. 60/214,028, filed Jun. 21, 2000; U.S. Application No. 60/280,705, filed Mar. 29, 2001; and U.S. Application No. 60/282,701, filed Apr. 9, 2001, the entire contents of which are incorporated herein by reference.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60214028 |
Jun 2000 |
US |
|
60280705 |
Mar 2001 |
US |
|
60282701 |
Apr 2001 |
US |